MedTrace Logo

DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection

NCT02772003 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2026-04-13

No results posted yet for this study

Summary

This phase I trial studies the side effects and best dose of deoxyribonucleic acid (DNA) vaccine therapy in treating patients with hepatitis C virus (HCV) infection that persists or progresses over a long period of time. Vaccines made from DNA may help the body build an effective immune response to kill cancer cells that express HCV infection.

Conditions

Interventions

BIOLOGICAL

Electroporation-Mediated Plasmid DNA Vaccine Therapy

Undergo electroporation

BIOLOGICAL

HCV DNA Vaccine INO-8000

Given IM

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

BIOLOGICAL

Rocakinogene Sifuplasmid

Given IM

Sponsors & Collaborators

Principal Investigators

  • Jeffrey M Jacobson · Mayo Clinic

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-06
Primary Completion
2020-03-04
Completion
2027-03-09

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02772003 on ClinicalTrials.gov